মূৰ আৰু ডিঙিৰ কেন্সাৰ
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
ক’ত যাব
ভাৰতৰ 1 খন হস্পিতালত এই trial-ৰ বাবে ৰোগী ভৰ্তি কৰা হৈছে।
ৰেজিষ্ট্ৰীৰ সাৰাংশ (কাৰিকৰী)
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
স্পনছৰ: NATCO Pharma Ltd.
ClinicalTrials.gov-ত NCT05283226
ৰেজিষ্ট্ৰীত অন্তিম আপডেট 23 Jan 2026 · আমাৰ দ্বাৰা পঢ়া হৈছে 20 Oct 2026